Abstract:Purpose: Neurofibromatosis type 1(NF1) and type 2(NF2) are both autosomal dominantly inherited disorders and originate from schwann cells. This study was done to investigate the genetic and proteomic profiles of the tumours.Methods: Mutational analyses of neurofibromatosis type 1 and type 2 genes (NF1 and NF2) in 15 NF1 and NF2 patients were carried out using Sanger sequencing. TMT-labeled spectrometry analysis was used to identify the proteome of neurofibromatosis type 1 and type 2 relative to nerve controls. Loss of heterozygosity were analysed for the candidate gene EPB41L3. Protein expression of tumour tissues/cultures was assessed by Western blots and/or immunofluorescence.Finds: DNA sequencing showed frequent mutations within NF1 or NF2 in the neurofibromatosis type 1 and type 2, respectively. 159 proteins were significantly differentially expressed in NF1 compared with normal nerves, and 180 proteins were significantly differentially expressed in NF2 compared with normal nerves. Among these, 11 were found commonly up-regulated and 30 down-regulated in both tumors. Among the commonly significantly down-regulated proteins in both tumors we consistently find EPB41L3.The EPB41L3 tumour suppressor showed the most significantly decreased expression, and existed predominantly at the cytoplasm of HEI193 and NF1 cell cultures. Western blot analysis identified the down-regulation in the NF1 and NF2 association with neurofibromin and merlin, respectively. LOH of EPB41L3 was more common among neurofibromatosis type 1(seen in 3 of 5 tumors, 60%) and least common among neurofibromatosis type 2 (2 of 10, 20%).Interpretation: Our data first get an insight into the common molecular mechanisms of neurofibroma, that indicates the potential role of EPB41L3 as a therapeutic target for this tumor syndrome.Funding Information: This work was supported by the National Natural Science Foundation of China (Grant No. 82171366 to Wei Chen; No. 82070541, 81600625, both to ML; 81771332, 81571184, both to CZ; 82172820 to JZ).and Grant No. 19ZR1447400 to Wei Chen. Jiangxi province outstanding poject (Grant No.20202ACBL216005 to Wei Chen); the Health Industry Clinical Research Project of Shanghai Municipal Health Commission (No. 20204125, to ML; No. 201840110, to SX); the Outstanding Leaders Training Program of Pudong Health Bureau of Shanghai (No. PWR12018-07, to CZ);the Key Discipline Construction Project of Pudong Health Bureau of Shanghai (No. PWZxk2017-23, to CZ); the Top-level Clinical Discipline Project of Shanghai Pudong (No. PWYgf2018-05, to CZ) .Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: Informed written consent was obtained from all patients donating tissue. This study was approved by the Institutional Review Board of the ethics committee of The shanghai east Hospital affiliated to School of Medicine, Shanghai Tong Ji University.

The Expression of Neurofibromin in Human Osteoblasts and Chondrocytes

The expression of neurofibromin in osteoblasts and chondrocytes from patients with congenital scoliosis

Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer.

Biological Features of Osteoblasts Isolated from Patients with Type 1 Neurofibromatosis

Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues

Expression of nerve growth factor family neurotrophins in a mouse osteoblastic cell line

NFATC1 and NFATC2 Expression Patterns in Human Osteochondromas

Neurofibromin and Its Inactivation of Ras Are Prerequisites for Osteoblast Functioning

Culture and identification of chondrocytes isolated from the vertebral endplate of patients with type I neurofibromatosis associated with atrophic changesin vitro

Proteomic and Genetic Analysis Reveals Loss of EPB41L3 Related to the Tumorigenesis of Neurofibromatosis Type 1 and Type 2

Differential expression of neuroleukin in osseous tissues and its involvement in mineralization during osteoblast differentiation.

Molecular dissection of somatic skeletal disease in Neurofibromatosis Type 1

Nfib promotes chondrocyte proliferation and inhibits differentiation by mildly regulating Sox9 and its downstream genes

Characterization of a neural-specific splicing form of the human neuregulin 3 gene involved in oligodendrocyte survival

SOX9 Promotes Collagen VI Secretion by Upregulating PCOLCE in Neurofibroma

Hyperactivation of P21ras and PI3K Cooperate to Alter Murine and Human Neurofibromatosis Type 1-Haploinsufficient Osteoclast Functions.

A Molecular Basis for Neurofibroma-Associated Skeletal Manifestations in NF1

Differential Gene Expression Profiles and Pathways Highlight the Role of Osteoimmunology in Neurofibromatosis Type 1-Related Dystrophic Scoliosis With Osteopenia

Neurofibromin expression by normal salivary glands

The Expression of Neurofibromin in Urinary Transitional Cell Carcinomas

Mechanism of SOX9 nuclear translocation induced by NF1 mutation promoting neurofibroma proliferation and collagen secretion